[PDF] Top 20 LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

... of LABA/LAMA FDCs vs LABAs or LAMAs or LABA/inhaled corticosteroid (ICS) FDCs on lung function (trough and peak FEV 1 ), dysp- nea (assessed using Transition Dyspnea Index [TDI] scores), quality of ... See full document

... adult patients who were capable of understanding the nature, signi fi cance and implications of the study and of forming a rational intention in the light of the facts were enrolled in the ...and patients in ... See full document

... a systematic review of the literature within the PubMed, Embase, ...terms: LABA, LAMA, ICS, FF, UMEC, VI, BDP, formoterol, fumarate, GB, BUD, tiotropium bro- mide, and ...for patients ... See full document

... in patients with stable COPD to be covered with the document, a thematic index (annex) was de fi ned by the scienti fi c committee in a kick-off virtual meeting, held on September 20, ...non-exhaustive ... See full document

... of patients experiencing at least one exacerbation, analyzed in trials with a treatment duration of 24 weeks or longer reporting data for this ...in patients with ... See full document

... meta-analysis, patients from all pair-wise meta-analysis have not been randomized to different trials and randomization would, therefore, not hold across the set of trials used for the ...mean COPD duration ... See full document

... (N=20,185). LABA/LAMA significantly improved trough forced expiratory volume in 1 second (FEV 1 ) from baseline to week 12 versus both LAMA and LABA/ICS ...with patients more likely to ... See full document

... Two systematic literature reviews were conducted to identify direct comparisons (head-to-head randomized controlled trials [RCTs]) and indirect comparisons (network meta- analyses [NMAs]; indirect treatment ... See full document

... these combinations are well tolerated in patients with moderate- to-severe chronic obstructive pulmonary disease ...inhaled, fixed-dose combination of two 24-hour bronchodilators, the ... See full document

... for patients with COPD. This review presents the clinical evidence that led to the approval of these triple therapies, discusses the role of ICS in patients with COPD, and presents data ... See full document

... of combinations in nebulizers for patients with ...weaker patients to use. Patients who are impaired, as well as those with low inspiratory flows, may also benefit from the ...of ... See full document

... for COPD is evolving ...(LAMA/LABA) fixed dose combination inhalers were introduced over the past 2 ...new LAMA/LABA inhalers could potentially reduce the use of ICS as ... See full document

... US patients are generally consistent with the results of other non-interventional stu- ...of patients with COPD initiating LAMA/ LABA FDCs in clinical practice in ...ndings, ... See full document

... for patients with symptomatic chronic obstructive lung disease (COPD) ...combined LABA/LAMA is a recommended treatment option in patients with moderate-to-severe COPD ...a ... See full document

... a LABA and a LAMA are currently available in ...once-daily LAMA and ...once-daily LAMA/LABA combination product to be approved in the United ...Both combinations take effect much ... See full document

... The results were driven by the relative short-term lung function benefit observed in the MTC, with tiotropium + olodaterol FDC dominating less effective treatments. Vary- ing the other clinical and cost parameters, ... See full document

... the fixed dose combination (FDC) of LABA and inhaled corticosteroids (LABA-ICS ...The patients were included in the analysis only if they had been prescribed a long-acting drug within 6 ... See full document

... individual patients such as their symptom pro fi le or lung function ...Canadian COPD Guidelines started recommending LAMA over SABA as fi rst-line therapy in ...for COPD) have generally ... See full document

... in COPD patients are often based on an expected poor ...when COPD patients should start PC is ...697 patients hospitalized for COPD ...in COPD patients in the short ... See full document

... of COPD. However, methylxanthine was the most commonly prescribed COPD medication over 6 years in ...for COPD in real clinical ...the COPD guideline and real ... See full document